WAKIX
Total Payments
$5.3M
Transactions
44,507
Doctors
8,853
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.8M | 23,031 | 6,259 |
| 2023 | $1.5M | 21,476 | 5,846 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 824 | 48.4% |
| Food and Beverage | $960,691 | 40,650 | 18.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $756,611 | 308 | 14.3% |
| Consulting Fee | $523,810 | 422 | 9.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $197,356 | 81 | 3.7% |
| Education | $148,366 | 1,730 | 2.8% |
| Travel and Lodging | $141,859 | 490 | 2.7% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.2% |
Payments by Type
General
$2.7M
43,683 transactions
Research
$2.6M
824 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | HARMONY BIOSCIENCES LLC | $795,117 | 3 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | HARMONY BIOSCIENCES LLC | $474,954 | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients with Prader-Willi Syndrome | HARMONY BIOSCIENCES LLC | $435,256 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension | HARMONY BIOSCIENCES LLC | $421,216 | 0 |
| Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | HARMONY BIOSCIENCES LLC | $358,687 | 0 |
| An Open-Label, Long-Term Safety Study to Evaluate the Safety and Tolerability of Pitolisant in Pediatric Patients with Prader-Willi Syndrome (PWS) who Participated in Study HBS-101-CL-003 | HARMONY BIOSCIENCES LLC | $71,109 | 0 |
| WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring | HARMONY BIOSCIENCES LLC | $11,175 | 5 |
| WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring | Harmony Biosciences LLC | $3,750 | 2 |
Ad
Manufacturing Companies
- HARMONY BIOSCIENCES LLC $3.8M
- Harmony Biosciences LLC $1.4M
- Harmony Biosciences Llc $100,164
Product Information
- Type Drug
- Total Payments $5.3M
- Total Doctors 8,853
- Transactions 44,507
About WAKIX
WAKIX is a drug associated with $5.3M in payments to 8,853 healthcare providers, recorded across 44,507 transactions in the CMS Open Payments database. The primary manufacturer is Harmony Biosciences LLC.
Payment data is available from 2023 to 2024. In 2024, $3.8M was paid across 23,031 transactions to 6,259 doctors.
The most common payment nature for WAKIX is "Unspecified" ($2.6M, 48.4% of total).
WAKIX is associated with 8 research studies, including "An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010" ($795,117).